OvaScience is developing a treatment to improve the odds for women to get pregnant through in vitro fertilization or IVF. The promise of its biotechnology has helped make OvaScience one of the hottest young companies on the Cambridge biotech scene. OvaScience has raised $40 million this year alone and hopes to land on the Nasdaq stock exchange by early next year. If it does, Michelle Dipp, at 36, would be among the youngest CEOs of a public company in Massachusetts.
Unlimited access to BostonGlobe.com for only 99 cents for the first 4 weeks.Sign up
Are you a home delivery subscriber?
Get FREE access as part of your print subscriptionStart Here
Contact us for help